These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 35545181

  • 1. Meta-analysis Comparing the Efficacy of Dobutamine Versus Milrinone in Acute Decompensated Heart Failure and Cardiogenic Shock.
    Biswas S, Malik AH, Bandyopadhyay D, Gupta R, Goel A, Briasoulis A, Fonarow GC, Lanier GM, Naidu SS.
    Curr Probl Cardiol; 2023 Aug; 48(8):101245. PubMed ID: 35545181
    [Abstract] [Full Text] [Related]

  • 2. Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure.
    Rodenas-Alesina E, Luis Scolari F, Wang VN, Brahmbhatt DH, Mihajlovic V, Fung NL, Otsuki M, Billia F, Overgaard CB, Luk A.
    ESC Heart Fail; 2023 Aug; 10(4):2577-2587. PubMed ID: 37322827
    [Abstract] [Full Text] [Related]

  • 3. Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock.
    Lewis TC, Aberle C, Altshuler D, Piper GL, Papadopoulos J.
    J Cardiovasc Pharmacol Ther; 2019 Mar; 24(2):130-138. PubMed ID: 30175599
    [Abstract] [Full Text] [Related]

  • 4. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
    Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, Ramirez FD, Harnett DT, Merdad A, Almufleh A, Weng W, Abdel-Razek O, Fernando SM, Kyeremanteng K, Bernick J, Wells GA, Chan V, Froeschl M, Labinaz M, Le May MR, Russo JJ, Hibbert B.
    N Engl J Med; 2021 Aug 05; 385(6):516-525. PubMed ID: 34347952
    [Abstract] [Full Text] [Related]

  • 5. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM, Crouch MA, Carroll NV, Oinonen MJ.
    Pharmacotherapy; 2006 Aug 05; 26(8):1078-85. PubMed ID: 16863484
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of milrinone and dobutamine in low cardiac output states: Systematic review and meta-analysis.
    Mathew R, Visintini SM, Ramirez FD, DiSanto P, Simard T, Labinaz M, Hibbert BM.
    Clin Invest Med; 2019 Jun 23; 42(2):E26-32. PubMed ID: 31228965
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Positive Inotropic Agents in the Management of Acute Decompensated Heart Failure.
    Kelly J, Cheng J, Malloy R, Lupi K.
    J Cardiovasc Pharmacol; 2020 May 23; 75(5):455-459. PubMed ID: 32091426
    [Abstract] [Full Text] [Related]

  • 8. Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.
    King JB, Shah RU, Sainski-Nguyen A, Biskupiak J, Munger MA, Bress AP.
    Pharmacotherapy; 2017 Jun 23; 37(6):662-672. PubMed ID: 28475215
    [Abstract] [Full Text] [Related]

  • 9. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
    Burkhardt BE, Rücker G, Stiller B.
    Cochrane Database Syst Rev; 2015 Mar 25; 2015(3):CD009515. PubMed ID: 25806562
    [Abstract] [Full Text] [Related]

  • 10. The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial.
    Parlow S, Di Santo P, Mathew R, Jung RG, Simard T, Gillmore T, Mao B, Abdel-Razek O, Ramirez FD, Marbach JA, Dick A, Glover C, Russo JJ, Froeschl M, Labinaz M, Fernando SM, Hibbert B, CAPITAL DOREMI investigators.
    Eur Heart J Acute Cardiovasc Care; 2021 Oct 01; 10(7):712-720. PubMed ID: 34382063
    [Abstract] [Full Text] [Related]

  • 11. Rehospitalization of Patients with Advanced Heart Failure Receiving Continuous, Palliative Dobutamine or Milrinone.
    Eaton RE, Kissling KT, Haas GJ, McLaughlin EM, Pickworth KK.
    Am J Cardiol; 2022 Dec 01; 184():80-89. PubMed ID: 36167736
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial.
    Prosperi-Porta G, Motazedian P, Di Santo P, Jung RG, Parlow S, Abdel-Razek O, Simard T, Hutson J, Malhotra N, Fu A, Ramirez FD, Froeschl M, Mathew R, Hibbert B, CAPITAL DOREMI investigators.
    J Cardiol; 2022 Oct 01; 80(4):358-364. PubMed ID: 35725945
    [Abstract] [Full Text] [Related]

  • 14. Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock.
    Jung RG, Di Santo P, Mathew R, Abdel-Razek O, Parlow S, Simard T, Marbach JA, Gillmore T, Mao B, Bernick J, Theriault-Lauzier P, Fu A, Lau L, Motazedian P, Russo JJ, Labinaz M, Hibbert B.
    J Am Heart Assoc; 2021 Nov 02; 10(21):e021570. PubMed ID: 34713704
    [Abstract] [Full Text] [Related]

  • 15. Palliative Inotropes in Advanced Heart Failure: Comparing Outcomes Between Milrinone and Dobutamine.
    Sami F, Acharya P, Noonan G, Maurides S, Al-Masry AA, Bajwa S, Parimi N, Boda I, Tran C, Goyal A, Mastoris I, Dalia T, Sauer A, Bakel AV, Shah Z.
    J Card Fail; 2022 Dec 02; 28(12):1683-1691. PubMed ID: 36122816
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of Inotropes on the Mortality in Patients With Septic Shock.
    Sato R, Ariyoshi N, Hasegawa D, Crossey E, Hamahata N, Ishihara T, Nasu M, Devendra G.
    J Intensive Care Med; 2021 Feb 02; 36(2):211-219. PubMed ID: 31793373
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.